Lumigan

Lumigan Uses, Dosage, Side Effects, Food Interaction and all others data.

Lumigan is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Lumigan reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Lumigan is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Lumigan may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.

High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Lumigan rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes.

Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.

Lumigan
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Lumigan
Generic	Bimatoprost
Bimatoprost Other Names	Bimatoprost, Bimatoprostum
Weight	03%w/v, 03%, , 0.1mg/ml, 0.01%, 0.03%
Type	Solution, Eye Drops, Solution/ Drops, Ophthalmic Solution
Formula	C₂₅H₃₇NO₄
Weight	Average: 415.5656 Monoisotopic: 415.272258677
Protein binding	Bimatoprost is about 88%-90% bound to plasma proteins.
Groups	Approved, Investigational
Therapeutic Class	Drugs for miotics and glaucoma
Manufacturer	Allergan India Pvt Ltd, Barrett Hodgson Pakistan (pvt) Ltd,, Eskayef Bangladesh Ltd, Allergan Ltd, Allergan Pharmaceuticals Ltd
Available Country	India, Pakistan, Bangladesh, United Kingdom, Canada, Australia, Saudi Arabia, United States, France, Netherlands, Portugal, Spain, Switzerland,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Lumigan is used for Ocular hypertension, Open-angle glaucoma

Lumigan is also used to associated treatment for these conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP), Ocular Hypertension

How Lumigan works

Lumigan imitates the effects of prostamides, specifically prostaglandin F2α. Lumigan mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Lumigan does not affect aqueous humor production.

Dosage

Lumigan dosage

Adult: Instill 1 drop into affected eye(s) once every night.

Side Effects

Common side effects are: Burning/stinging/irritation/ redness/discomfort of the eye, Feeling as if something is in your eye, Dry eyes, Watering eyes, Temporary unstable vision, Increased sensitivity to light, Dizziness.

Toxicity

No information is available at this time regarding bimatoprost overdose in humans. Provide supportive symptomatic treatment if an overdose occurs.

Precaution

May increase pigmentation of the iris, periorbital tissue and eyelashes. Active intraocular inflammation. Safety and efficacy have not been evaluated in the treatment of inflammatory, neovascular or angle closure glaucoma. Ensure at least an interval of 5 minutes between admin of ophthalmic preparations. Contact lenses should be removed prior to admin. Pregnancy, lactation.

Interaction

There is not known drug interactions and none well documented.

Food Interaction

No interactions found.

Volume of Distribution

The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.

Elimination Route

This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Lumigan was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing.

One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Lumigan effects may last up to 24 hours.

Half Life

The elimination half-life of bimatoprost is approximately 45 minutes.

Clearance

The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.

Elimination Route

One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.

Pregnancy & Breastfeeding use

Pregnancy Category C. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.